Best practices: Appropriate use of the new $β$-lactam/$β$-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa. Brink, A. J, Coetzee, J., Richards, G. A, Feldman, C., Lowman, W., Tootla, H. D, Miller, M. G A, Niehaus, A. J, Wasserman, S., Perovic, O., Govind, C. N, Schellack, N., & Mendelson, M. Southern African Journal of Infectious Diseases, 37(1):a453, oct, 2022. ![Best practices: Appropriate use of the new $β$-lactam/$β$-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Antibiotic stewardship of hospital-acquired infections because of difficult-to-treat resistant (DTR) Gram-negative bacteria is a global challenge. Their increasing prevalence in South Africa has required a shift in prescribing in recent years towards colistin, an antibiotic of last resort. High toxicity levels and developing resistance to colistin are narrowing treatment options further. Recently, two new $β$-lactam/$β$-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam were registered in South Africa, bringing hope of new options for management of these life-threatening infections. However, with increased use in the private sector, increasing levels of resistance to ceftazidime-avibactam are already being witnessed, putting their long-term viability as treatment options of last resort, in jeopardy. This review focuses on how these two vital new antibiotics should be stewarded within a framework that recognises the resistance mechanisms currently predominant in South Africa's multi-drug and DTR Gram-negative bacteria. Moreover, the withholding of their use for resistant infections that can be treated with currently available antibiotics is a critical part of stewardship, if these antibiotics are to be conserved in the long term.
@article{Brink2022,
abstract = {Antibiotic stewardship of hospital-acquired infections because of difficult-to-treat resistant (DTR) Gram-negative bacteria is a global challenge. Their increasing prevalence in South Africa has required a shift in prescribing in recent years towards colistin, an antibiotic of last resort. High toxicity levels and developing resistance to colistin are narrowing treatment options further. Recently, two new $\beta$-lactam/$\beta$-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam were registered in South Africa, bringing hope of new options for management of these life-threatening infections. However, with increased use in the private sector, increasing levels of resistance to ceftazidime-avibactam are already being witnessed, putting their long-term viability as treatment options of last resort, in jeopardy. This review focuses on how these two vital new antibiotics should be stewarded within a framework that recognises the resistance mechanisms currently predominant in South Africa's multi-drug and DTR Gram-negative bacteria. Moreover, the withholding of their use for resistant infections that can be treated with currently available antibiotics is a critical part of stewardship, if these antibiotics are to be conserved in the long term.},
author = {Brink, Adrian J and Coetzee, Jennifer and Richards, Guy A and Feldman, Charles and Lowman, Warren and Tootla, Hafsah D and Miller, Malcolm G A and Niehaus, Abraham J and Wasserman, Sean and Perovic, Olga and Govind, Chetna N and Schellack, Natalie and Mendelson, Marc},
doi = {10.4102/SAJID.V37I1.453},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Brink et al. - 2022 - Best practices Appropriate use of the new $\beta$-lactam$\beta$-lactamase inhibitor combinations, ceftazidime-avibactam and ce.pdf:pdf},
issn = {2313-1810},
journal = {Southern African Journal of Infectious Diseases},
keywords = {Enterobacterales,Gram,Infectious diseases,OA,Pseudomonas aeruginosa,antimicrobial stewardship,avibactam,bacterial,ceftazidime,ceftolozane,clinical,communicable,diagnosis,epidemiology,fund{\_}not{\_}ack,fungal,guideline,laboratory,lactam/$\beta$,lactamase inhibitor combinations,negatives,parasitic,tazobactam,treatment,viral,$\beta$},
mendeley-tags = {OA,fund{\_}not{\_}ack,guideline},
month = {oct},
number = {1},
pages = {a453},
title = {{Best practices: Appropriate use of the new $\beta$-lactam/$\beta$-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa}},
url = {https://sajid.co.za/index.php/sajid/article/view/453/1065 https://sajid.co.za/index.php/sajid/article/view/453/1066 https://sajid.co.za/index.php/sajid/article/view/453/1067 https://sajid.co.za/index.php/sajid/article/view/453},
volume = {37},
year = {2022}
}
Downloads: 0
{"_id":"Ra5SEjcDJeeG2YY7a","bibbaseid":"brink-coetzee-richards-feldman-lowman-tootla-miller-niehaus-etal-bestpracticesappropriateuseofthenewlactamlactamaseinhibitorcombinationsceftazidimeavibactamandceftolozanetazobactaminsouthafrica-2022","author_short":["Brink, A. J","Coetzee, J.","Richards, G. A","Feldman, C.","Lowman, W.","Tootla, H. D","Miller, M. G A","Niehaus, A. J","Wasserman, S.","Perovic, O.","Govind, C. N","Schellack, N.","Mendelson, M."],"bibdata":{"bibtype":"article","type":"article","abstract":"Antibiotic stewardship of hospital-acquired infections because of difficult-to-treat resistant (DTR) Gram-negative bacteria is a global challenge. Their increasing prevalence in South Africa has required a shift in prescribing in recent years towards colistin, an antibiotic of last resort. High toxicity levels and developing resistance to colistin are narrowing treatment options further. Recently, two new $β$-lactam/$β$-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam were registered in South Africa, bringing hope of new options for management of these life-threatening infections. However, with increased use in the private sector, increasing levels of resistance to ceftazidime-avibactam are already being witnessed, putting their long-term viability as treatment options of last resort, in jeopardy. This review focuses on how these two vital new antibiotics should be stewarded within a framework that recognises the resistance mechanisms currently predominant in South Africa's multi-drug and DTR Gram-negative bacteria. Moreover, the withholding of their use for resistant infections that can be treated with currently available antibiotics is a critical part of stewardship, if these antibiotics are to be conserved in the long term.","author":[{"propositions":[],"lastnames":["Brink"],"firstnames":["Adrian","J"],"suffixes":[]},{"propositions":[],"lastnames":["Coetzee"],"firstnames":["Jennifer"],"suffixes":[]},{"propositions":[],"lastnames":["Richards"],"firstnames":["Guy","A"],"suffixes":[]},{"propositions":[],"lastnames":["Feldman"],"firstnames":["Charles"],"suffixes":[]},{"propositions":[],"lastnames":["Lowman"],"firstnames":["Warren"],"suffixes":[]},{"propositions":[],"lastnames":["Tootla"],"firstnames":["Hafsah","D"],"suffixes":[]},{"propositions":[],"lastnames":["Miller"],"firstnames":["Malcolm","G","A"],"suffixes":[]},{"propositions":[],"lastnames":["Niehaus"],"firstnames":["Abraham","J"],"suffixes":[]},{"propositions":[],"lastnames":["Wasserman"],"firstnames":["Sean"],"suffixes":[]},{"propositions":[],"lastnames":["Perovic"],"firstnames":["Olga"],"suffixes":[]},{"propositions":[],"lastnames":["Govind"],"firstnames":["Chetna","N"],"suffixes":[]},{"propositions":[],"lastnames":["Schellack"],"firstnames":["Natalie"],"suffixes":[]},{"propositions":[],"lastnames":["Mendelson"],"firstnames":["Marc"],"suffixes":[]}],"doi":"10.4102/SAJID.V37I1.453","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Brink et al. - 2022 - Best practices Appropriate use of the new $β$-lactam$β$-lactamase inhibitor combinations, ceftazidime-avibactam and ce.pdf:pdf","issn":"2313-1810","journal":"Southern African Journal of Infectious Diseases","keywords":"Enterobacterales,Gram,Infectious diseases,OA,Pseudomonas aeruginosa,antimicrobial stewardship,avibactam,bacterial,ceftazidime,ceftolozane,clinical,communicable,diagnosis,epidemiology,fund_not_ack,fungal,guideline,laboratory,lactam/$β$,lactamase inhibitor combinations,negatives,parasitic,tazobactam,treatment,viral,$β$","mendeley-tags":"OA,fund_not_ack,guideline","month":"oct","number":"1","pages":"a453","title":"Best practices: Appropriate use of the new $β$-lactam/$β$-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa","url":"https://sajid.co.za/index.php/sajid/article/view/453/1065 https://sajid.co.za/index.php/sajid/article/view/453/1066 https://sajid.co.za/index.php/sajid/article/view/453/1067 https://sajid.co.za/index.php/sajid/article/view/453","volume":"37","year":"2022","bibtex":"@article{Brink2022,\r\nabstract = {Antibiotic stewardship of hospital-acquired infections because of difficult-to-treat resistant (DTR) Gram-negative bacteria is a global challenge. Their increasing prevalence in South Africa has required a shift in prescribing in recent years towards colistin, an antibiotic of last resort. High toxicity levels and developing resistance to colistin are narrowing treatment options further. Recently, two new $\\beta$-lactam/$\\beta$-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam were registered in South Africa, bringing hope of new options for management of these life-threatening infections. However, with increased use in the private sector, increasing levels of resistance to ceftazidime-avibactam are already being witnessed, putting their long-term viability as treatment options of last resort, in jeopardy. This review focuses on how these two vital new antibiotics should be stewarded within a framework that recognises the resistance mechanisms currently predominant in South Africa's multi-drug and DTR Gram-negative bacteria. Moreover, the withholding of their use for resistant infections that can be treated with currently available antibiotics is a critical part of stewardship, if these antibiotics are to be conserved in the long term.},\r\nauthor = {Brink, Adrian J and Coetzee, Jennifer and Richards, Guy A and Feldman, Charles and Lowman, Warren and Tootla, Hafsah D and Miller, Malcolm G A and Niehaus, Abraham J and Wasserman, Sean and Perovic, Olga and Govind, Chetna N and Schellack, Natalie and Mendelson, Marc},\r\ndoi = {10.4102/SAJID.V37I1.453},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Brink et al. - 2022 - Best practices Appropriate use of the new $\\beta$-lactam$\\beta$-lactamase inhibitor combinations, ceftazidime-avibactam and ce.pdf:pdf},\r\nissn = {2313-1810},\r\njournal = {Southern African Journal of Infectious Diseases},\r\nkeywords = {Enterobacterales,Gram,Infectious diseases,OA,Pseudomonas aeruginosa,antimicrobial stewardship,avibactam,bacterial,ceftazidime,ceftolozane,clinical,communicable,diagnosis,epidemiology,fund{\\_}not{\\_}ack,fungal,guideline,laboratory,lactam/$\\beta$,lactamase inhibitor combinations,negatives,parasitic,tazobactam,treatment,viral,$\\beta$},\r\nmendeley-tags = {OA,fund{\\_}not{\\_}ack,guideline},\r\nmonth = {oct},\r\nnumber = {1},\r\npages = {a453},\r\ntitle = {{Best practices: Appropriate use of the new $\\beta$-lactam/$\\beta$-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa}},\r\nurl = {https://sajid.co.za/index.php/sajid/article/view/453/1065 https://sajid.co.za/index.php/sajid/article/view/453/1066 https://sajid.co.za/index.php/sajid/article/view/453/1067 https://sajid.co.za/index.php/sajid/article/view/453},\r\nvolume = {37},\r\nyear = {2022}\r\n}\r\n","author_short":["Brink, A. J","Coetzee, J.","Richards, G. A","Feldman, C.","Lowman, W.","Tootla, H. D","Miller, M. G A","Niehaus, A. J","Wasserman, S.","Perovic, O.","Govind, C. N","Schellack, N.","Mendelson, M."],"key":"Brink2022","id":"Brink2022","bibbaseid":"brink-coetzee-richards-feldman-lowman-tootla-miller-niehaus-etal-bestpracticesappropriateuseofthenewlactamlactamaseinhibitorcombinationsceftazidimeavibactamandceftolozanetazobactaminsouthafrica-2022","role":"author","urls":{"Paper":"https://sajid.co.za/index.php/sajid/article/view/453/1065 https://sajid.co.za/index.php/sajid/article/view/453/1066 https://sajid.co.za/index.php/sajid/article/view/453/1067 https://sajid.co.za/index.php/sajid/article/view/453"},"keyword":["Enterobacterales","Gram","Infectious diseases","OA","Pseudomonas aeruginosa","antimicrobial stewardship","avibactam","bacterial","ceftazidime","ceftolozane","clinical","communicable","diagnosis","epidemiology","fund_not_ack","fungal","guideline","laboratory","lactam/$β$","lactamase inhibitor combinations","negatives","parasitic","tazobactam","treatment","viral","$β$"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh"],"keywords":["enterobacterales","gram","infectious diseases","oa","pseudomonas aeruginosa","antimicrobial stewardship","avibactam","bacterial","ceftazidime","ceftolozane","clinical","communicable","diagnosis","epidemiology","fund_not_ack","fungal","guideline","laboratory","lactam/$β$","lactamase inhibitor combinations","negatives","parasitic","tazobactam","treatment","viral","$β$"],"search_terms":["best","practices","appropriate","use","new","lactam","lactamase","inhibitor","combinations","ceftazidime","avibactam","ceftolozane","tazobactam","south","africa","brink","coetzee","richards","feldman","lowman","tootla","miller","niehaus","wasserman","perovic","govind","schellack","mendelson"],"title":"Best practices: Appropriate use of the new $β$-lactam/$β$-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa","year":2022}